Iovance Biotherapeutics, Inc.
IOVA · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.15 | -0.06 | 1.01 | 0.48 |
| FCF Yield | -13.02% | -10.22% | -3.43% | -2.15% |
| EV / EBITDA | -4.87 | -8.95 | -29.36 | -35.45 |
| Quality | ||||
| ROIC | -14.73% | -13.98% | -11.03% | -9.89% |
| Gross Margin | 5.48% | -0.85% | 38.20% | 31.99% |
| Cash Conversion Ratio | 0.86 | 0.60 | 0.89 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | 607.54% | 904.91% | 5,968,981.69% | 5,474,371.22% |
| Free Cash Flow Growth | 31.84% | -41.88% | -26.45% | 38.04% |
| Safety | ||||
| Net Debt / EBITDA | 0.78 | 1.10 | 0.77 | 1.09 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.14 | 0.76 | 0.88 | 1.03 |
| Cash Conversion Cycle | 118.30 | 196.49 | 132.13 | 101.29 |